logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn Inc to begin enrolling severe and critically ill coronavirus patients in Phase 2b/3 trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company can now initiate its Phase 2b/3 trial for severe and critically ill coronavirus patients.

What's more, Pourhassan says it is collaborating with the UK’s Department of Health to provide emergency access to leronlimab the company’s investigational drug for treating coronavirus patients.

Quick facts: CytoDyn Inc.

Price: 3.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.49 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

5 days, 6 hours ago

2 min read